During the last session, Atossa Therapeutics, Inc. (NASDAQ:ATOS)’s traded shares were 5,492,617, with the beta value of the company hitting 2.22. At the end of the trading day, the stock’s price was $2.16, reflecting an intraday gain of 5.88% or $0.12. The 52-week high for the ATOS share is $5.08, that puts it down -135.19% from that peak though still a striking +62.5% gain since the share price plummeted to a 52-week low of $0.81. The company’s market capitalization is $260.98 Million, and the average intraday trading volume over the past 10 days was 7.46 Million shares, and the average trade volume was 24.63 Million shares over the past three months.
Atossa Therapeutics, Inc. (ATOS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2. ATOS has a Sell rating from none of the analyst(s) out of 2 analysts who have looked at this stock. Neither of the analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 2 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.05.
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Trading Information
Atossa Therapeutics, Inc. (ATOS) registered a 5.88% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.37% in intraday trading to $2.19- this Wednesday, Apr 07, hitting a weekly high. The stock’s 5-day price performance is 5.37%, and it has moved by -3.14% in 30 days. Based on these gigs, the overall price performance for the year is 127.37%. The short interest in Atossa Therapeutics, Inc. (NASDAQ:ATOS) is 6.59 Million shares and it means that shorts have 0.27 day(s) to cover.
The consensus price target of analysts on Wall Street is $6.38, which implies an increase of 195.37% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $7.75 respectively. As a result, ATOS is trading at a discount of 258.8% off the target high and 131.48% off the low.
Atossa Therapeutics, Inc. (ATOS) projections and forecasts
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated 0%. While earnings are projected to return 59.4% in 2021, the next five years will return 0% per annum.
Atossa Therapeutics, Inc. (NASDAQ:ATOS)’s Biggest Investors
Atossa Therapeutics, Inc. insiders own 0.04% of total outstanding shares while institutional holders control 7.59%, with the float percentage being 7.59%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 20 institutions own stock in it. As of Dec 30, 2020, the company held over 518.11 Thousand shares (or 0.43% of all shares), a total value of $492.2 Thousand in shares.
The next largest institutional holding, with 492.8 Thousand shares, is of Renaissance Technologies, LLC’s that is approximately 0.41% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $468.16 Thousand.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also, the Mutual Funds coming in first place with the largest holdings of Atossa Therapeutics, Inc. (ATOS) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2020 indicates that Vanguard Total Stock Market Index Fund owns about 397,420 shares. This amounts to just over 0.33 percent of the company’s overall shares, with a $377.55 Thousand market value. The same data shows that the other fund manager holds slightly less at 120.69 Thousand, or about 0.1% of the stock, which is worth about $114.65 Thousand.